Studys Of Pharmacodynamics Of LaoSunKangFu Tablet

Studys of pharmacodynamics of LaoSunKangFu Tablet Objective: to observe the influence of the cute soft tissue injury disease. Method:knalgesia was tested by scald-plate caused sole-ache, actic acid caused bellyache. The anti-inflammtory as tested by auricle swelling carrageenan caused arthroncus. Blood-activating and stasis-removing was tested by establishing cute cold pathogens-induced blood stasis rat model and microcirculation disturbance state rat model by means of dripping adrenine on the mensentery. The Resisting the acute soft tissue injury in caused by strick and resisting the oxidation was tested by establishing the The freely falling body damages models. The kidney-notifying was tested by Acetic acid hydrocortisone-caused kidney asthenia of mice. Result: All of the experimental results showed that there were Significant differences between the treatment groups and the control groups (P<0. 05)ruanshang-tablets have obvious Analgesia, anti- inflammtory ,promoting blood circulation and removing blood stasis, resisting the acute soft tissue injury, resisting the oxidation, the kidney -notifying actions. Conclusion: Ruanshang tablets have action of blood - activating and analgesia, kidney-notifying, have a good improving to the cute soft tissue injury.Studys of Toxic Mechanism of LaoSunKangFu TabletObjective: to evaluate the security of LaoSunKangFu Tablet and to supply experimental evidence for safety of drugs in clinic. Methods: the acute toxic experiment in mice and the chronic toxic expriment(continued stomach irrigation for 12 weeks) in rats. Results: that single stomach irrigation could not enough induce the mice death, the maximum tolerance doses(MTD) in a day were 220g/kg which was equivalent to 386 times of Clinical daily doses according to avoirdupois .The non-toxicity doses in the chronic toxic experiment were 55g/kg which was equivalent to 96 times of Clinical daily doses according to avoirdupois. Conclusion: the LaoSunKangFu Tablet has low toxicity, and this provides the experimental basis for the security of recommended clinical daily 0. 57g/kg and for 3 weeks as one period of treatment.